HCPCS code Q5105: Retacrit billing guide for ESRD dialysis

Key Takeaways

HCPCS code Q5105 describes injection, epoetin alfa-epbx (Retacrit), biosimilar, for ESRD on dialysis, billed in 100-unit increments

Q5105 is restricted to patients with end-stage renal disease actively on dialysis; non-ESRD use requires Q5106 instead

CMS does not list Q5105 on its single-dose container registry, so JW and JZ wastage modifiers may not apply to this code

Pabau’s claims management software helps dialysis facility billing teams track drug units, attach required diagnosis codes, and reduce Q5105 claim denials

HCPCS code Q5105 is the official code for: Injection, epoetin alfa-epbx, biosimilar, (Retacrit) (for ESRD on dialysis), 100 units. Pfizer/Hospira manufactures Retacrit, a biosimilar to epoetin alfa (the reference product marketed as Epogen and Procrit). CMS introduced this code through Change Request CR10818 in June 2018. It specifically captures anemia management for end-stage renal disease patients on dialysis.

The code falls under the HCPCS Level II temporary Q-code category for Anti-Inflammatory Medication and Chemotherapy Medication (Q5103-Q5111), which the Centers for Medicare and Medicaid Services (CMS) maintains. Currently, it is valid for 2026 and carries no scheduled sunset date at time of publication.

Who can bill HCPCS code Q5105?

Eligibility to bill Q5105 is narrower than many coders assume. To qualify, a patient must meet two core conditions.

• Patient has ESRD: The patient must have a confirmed end-stage renal disease diagnosis, typically documented with ICD-10-CM code N18.6 (End-stage renal disease).
• Patient is actively on dialysis: The patient must be receiving hemodialysis or peritoneal dialysis at the time of administration. Patients with chronic kidney disease who are not yet on dialysis do not qualify.
• Setting: Q5105 is primarily billed by ESRD dialysis facilities, hospital outpatient departments providing dialysis, and physician offices administering Retacrit to ESRD dialysis patients under the buy-and-bill model.

Sometimes a patient needs Retacrit for a non-ESRD indication, such as chemotherapy-induced anemia. In that case, the correct code is Q5106, which payers bill in 1,000-unit increments. Using Q5105 for non-ESRD patients is a common mismatch, and it triggers denials. CMS’s Medicare Coverage Database Article A56795 states this clearly: HCPCS codes J0882, J0887, Q4081, and Q5105 are intended for use only with patients who have ESRD and are on dialysis.

Q5105 billing units and dose calculation

The billing unit for Q5105 is 100 units of epoetin alfa-epbx per claim line. This means the unit count on each claim must reflect the total dose divided by 100.

Round down when a dose does not divide evenly into whole 100-unit increments. Pfizer supplies Retacrit in multiple vial concentrations, so confirm the NDC number from the package before billing. In addition, some payers require you to report the National Drug Code (NDC) alongside Q5105 on the claim. Always check individual payer policies, because NDC reporting requirements vary.

Streamline your dialysis facility billing

Pabau's claims management tools help nephrology and dialysis billing teams track drug units, attach correct diagnosis codes, and catch errors before claims go out the door.

Book a demo

HCPCS code Q5105 coverage and Medicare reimbursement

Medicare Part B covers Retacrit (Q5105) for ESRD patients on dialysis under the ESRD Prospective Payment System (PPS), also called the ESRD bundle. Therefore, understanding where Q5105 sits within that bundle matters for billing correctly.

ESRD bundle vs. separate billing

Under the ESRD PPS, the bundled payment that Medicare pays to ESRD facilities typically includes erythropoiesis-stimulating agents (ESAs) such as Retacrit. As a result, the facility generally cannot bill Q5105 as a separate line item on top of the bundle rate. Billing Q5105 separately constitutes overbilling, and it carries a significant compliance risk. For practices subject to Medicare audits, HIPAA compliance and billing accuracy go hand in hand.

Exceptions exist when a provider administers Retacrit to an ESRD patient outside the dialysis setting. For example, a physician office that is not the billing dialysis facility may give the drug. In that context, the office may bill Q5105 under the buy-and-bill model, subject to Medicare’s drug payment policy for physician fee schedule payers. Always confirm the patient’s primary payer and setting first, before you decide whether to bundle or bill separately.

Medicare fee schedule for Q5105

CMS updates the reimbursement rates for Q5105 every year. To verify the current payment amount for your MAC jurisdiction, use the CMS Physician Fee Schedule lookup tool. Rates differ by geographic locality, and the annual conversion factor update affects them too. Because any figures in third-party references may be out of date, always use the live CMS tool for current-year billing decisions.

State Medicaid programs set their own rates for Q5105 independently of Medicare. Indiana’s IHCP, for example, published updated pricing in September 2022 (Banner Page BR202237). Other state Medicaid programs follow similar quarterly update cycles. In addition, commercial payers such as Premera Blue Cross and UnitedHealthcare maintain their own ESA medical policies. These policies may require prior authorization for Retacrit, even when the patient is Medicare-primary. Therefore, coordinating care across multiple payers means you must verify each payer’s current ESA policy first.

Modifiers and JW/JZ applicability for HCPCS code Q5105

CMS introduced the JW and JZ modifiers to track drug wastage from single-dose containers. JW flags discarded drug from a single-dose vial, while JZ confirms that none was discarded. Whether these modifiers apply to Q5105 is a common coder question, and it has a specific answer.

According to CMS guidelines, which manufacturer billing resources cite, CMS does not include Q5105 on its list of HCPCS codes for single-dose containers. As a result, the JW and JZ wastage modifiers may not apply when you bill Q5105. Still, practices should verify this position against current CMS JW/JZ guidance before they finalize a coding policy, because CMS updates these modifier lists periodically. Billing JW on Q5105 without authorization risks claim rejection or audit exposure.

Other modifiers that may apply depending on setting and payer policy include:

• Modifier KX: Use this when the claim meets Medicare coverage requirements and documentation is on file. Some payers require KX on ESA claims to confirm medical necessity.
• Modifier GY: This indicates that the item or service is statutorily excluded, or that it does not meet any Medicare benefit definition. Use it when you bill a non-covered indication.
• Modifier GZ: This indicates that the provider expects Medicare to deny the claim as not medically necessary and no advance beneficiary notice (ABN) was issued. It triggers an automatic denial, and because no ABN is on file the provider is liable and cannot bill the patient. When an ABN is on file and you want to preserve the ability to bill the patient, use modifier GA instead.

Effective digital documentation workflows help ensure that the right modifier justification is on file before you submit claims. As a result, they reduce the risk of retrospective audit findings.

Diagnosis codes used with Q5105

Two ICD-10-CM codes serve as the primary diagnosis anchors for Q5105 claims. To support medical necessity, you must document both accurately in the medical record. Complete patient records that clearly link the diagnosis to the treatment date are essential for claim approval and audit defense.

• N18.6 – End-stage renal disease: This is the primary indicator that the patient qualifies for Q5105. The code confirms ESRD status, and it distinguishes Q5105 (ESRD on dialysis) from Q5106 (non-ESRD use).
• D63.1 – Anemia in chronic kidney disease: This secondary diagnosis establishes medical necessity for the ESA therapy. Because clinicians prescribe Retacrit to treat symptomatic anemia from renal failure, this code directly justifies the drug.

Sequence N18.6 as the principal diagnosis when ESRD is the condition chiefly responsible for the encounter. D63.1 then follows as an additional diagnosis. In addition, some payers accept or require a Z code, such as Z99.2 (Dependence on renal dialysis), to confirm active dialysis status. Finally, check your MAC’s local coverage determination (LCD) and payer-specific policies for sequencing rules.

Q5105 vs. Q5106 and related ESA billing codes

Understanding how Q5105 relates to other erythropoiesis-stimulating agent codes prevents miscoding and payer confusion. The table below summarizes the key distinctions.

Q5105 vs. Q5106: The critical distinction is the patient population. Q5105 applies exclusively to ESRD patients on dialysis, at 100 units per increment. Q5106, by contrast, covers all other Retacrit indications, at the larger 1,000-unit increment. Suppose a dialysis patient also receives Retacrit for chemotherapy-induced anemia during the same encounter. That scenario requires both codes on separate claim lines, each with the appropriate diagnosis linkage. To keep code-to-diagnosis linkage correct across complex encounters, consult your EHR and billing system integration.

Q5105 vs. Q4081: Q4081 covers epoetin alfa (the reference brand, Epogen or Procrit) for ESRD on dialysis, while Q5105 is the biosimilar equivalent. The clinical outcome may be comparable, but the codes are not interchangeable for billing. Therefore, bill the code that matches the drug you actually administer.

Documentation requirements for HCPCS code Q5105

CMS and commercial payers expect specific documentation on file before and during each Retacrit administration. In fact, missing elements are the leading cause of post-payment audit recoupments for ESA claims.

• ESRD diagnosis confirmation: Medical records must document the N18.6 diagnosis with the treating nephrologist’s or facility physician’s attestation. Labs supporting ESRD staging are strong supporting documentation.
• Active dialysis on date of service: The treatment note or dialysis session log must show that dialysis occurred on the same date as Retacrit administration. Alternatively, it must document the dialysis schedule when administration falls on non-dialysis days under the treatment protocol.
• Anemia workup: Hemoglobin/hematocrit values that establish medical necessity for ESA therapy. CMS and most commercial payers require hemoglobin below a defined threshold before approving ESA administration.
• Physician order: A signed physician order specifying Retacrit (or epoetin alfa-epbx biosimilar), dose, route, and frequency.
• Drug lot number and NDC: Record the National Drug Code from the administered vial. Some payers require NDC reporting on the claim itself.
• Response monitoring: Ongoing labs showing hemoglobin response and any dose adjustments. ESA therapy without documented monitoring is a red flag in CMS coverage audits.

Organized medical forms and documentation workflows capture all required data points at the point of care, rather than during a later audit. Prescription management software that records drug lot numbers and administration details at dispensing time eliminates the most common documentation gaps. In addition, practices that want to modernize their record-keeping can explore how practice management software centralizes clinical and billing documentation in one workflow.

Common denial reasons and how to address them

Q5105 claims deny for predictable reasons. Fortunately, front-end edits in the billing workflow prevent most of them.

• Non-ESRD patient billed with Q5105: Payer systems check diagnosis codes. N18.6 must be present. If the patient is pre-dialysis CKD, use Q5106 instead. Patient scheduling and appointment management that tracks dialysis status in the patient record prevents this mismatch before it reaches billing.
• Incorrect unit count: Billing 1 unit when the dose is 1,000 units (correct units = 10) is a common data-entry error. Build a dose-to-units calculator into your pre-submission checklist.
• Missing NDC when required: Some payers auto-deny drug claims lacking NDC. Include the NDC on every claim as a safe default.
• Bundle billing overlap: ESRD facilities billing Q5105 as a separate line in addition to the ESRD bundle rate will receive denials. Confirm setting and billing entity before unbundling.
• Prior authorization not obtained: Commercial payers including UHC and Premera require prior authorization for ESA therapy. Payers deny retroactive claims that lack authorization on file, with no appeal recourse. HIPAA-compliant documentation practices that include PA tracking protect against this exposure.

Conclusion

HCPCS code Q5105 is a narrow-use code with strict patient eligibility, specific unit-calculation rules, and modifier restrictions. These details trip up even experienced billers. To get the diagnosis linkage, unit math, and bundling determination right on every claim, rely on consistent pre-submission checklists rather than memory.

Pabau’s claims management software gives billing teams a structured environment to capture drug units, attach diagnosis codes, and flag missing documentation before claims go out. To see how it fits into a nephrology or multi-specialty billing workflow, book a demo.

Continue your research

Need to understand the broader ESA billing landscape? HIPAA compliance for medical offices covers documentation and audit-readiness requirements that apply across all drug billing scenarios.

Managing complex multi-payer billing workflows? Pabau’s inventory management software tracks drug stock, lot numbers, and administration records to support NDC reporting requirements.

Frequently Asked Questions